|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.864 EUR | -0.35% |
|
+2.95% | -15.27% |
| 06-29 | DBV Expects Viaskin Peanut Patch BLA Submission in Q3 After FDA Feedback | MT |
| 06-29 | DBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 970M | - | ||||
| 318B | |||||
| 72.22B | |||||
| 8.89B | |||||
| 8.25B | |||||
| 4.23B |
- Stock Market
- Stocks
- DBV Stock
- Charts DBV Technologies
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
